Treatment with the selective PPARδ agonist GW501516 markedly accelerated mammary carcinogenesis, particularly in MMTV-PDK1 mice, and the reduction in tumor latency correlated with a metabolic gene expression and metabolomic signature that differed from wild-type animals. The gene discussed is PDK1; the disease is neoplasm.